|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123 USD | -1.35% |
|
-1.13% | -11.63% |
| Apr. 22 | Bernstein Adjusts Price Target on Illumina to $129 From $150 | MT |
| Apr. 22 | Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept | MT |
BRUSSELS (Reuters) - The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail, it said in a statement on Friday.
The U.S. gene sequencing company Illumina had announced late last year to divest Grail, after the companies battled both U.S. and European antitrust enforcers for more than two years and faced fierce opposition from activist investor Carl Icahn.
(Writing by Nette Nöstlinger, Editing by Charlotte Van Campenhout)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 123 USD | -1.35% | -1.13% | 19.86B | ||
| 17.64 USD | +0.51% | +3.76% | 7.53B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -11.63% | 19.86B | |
| +7.15% | 220B | |
| +6.60% | 183B | |
| +9.86% | 133B | |
| +24.32% | 107B | |
| -0.95% | 63.05B | |
| +11.04% | 51.74B | |
| +4.81% | 50.47B | |
| -1.43% | 40.91B | |
| +24.40% | 31.91B |
ILLUMINA, INC. 
